Sugi Predict

Sugi Predict / Compounds / SCHEMBL200820

SCHEMBL200820

SCHEMBL200820

[CH2]CCCCC(C)CCCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ ACE2 Q9BYF1 1/20 0.43
▸ OPRM1 P35372 1/20 0.40
▸ DNM1 Q05193 2/20 0.36
▸ PRKD3 O94806 1/20 0.34
▸ PRKCG P05129 1/20 0.34
▸ PRKCB P05771 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ PRKCH P24723 1/20 0.34
▸ PRKCI P41743 1/20 0.34
▸ PRKCE Q02156 1/20 0.34
▸ PRKCQ Q04759 1/20 0.34
▸ PRKCZ Q05513 1/20 0.34
▸ PRKCD Q05655 1/20 0.34
▸ PRKD1 Q15139 1/20 0.34
▸ CA1 P00915 2/20 0.33
▸ SPHK1 Q9NYA1 1/20 0.33
▸ TP53 P04637 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27038952 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL9745732 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL27039032 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL5086553 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL6764178 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL25185980 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL7104064 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL7101548 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL199794 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3
SCHEMBL27039098 0.97 ACE2 (0.47) LMNAACE2OPRM1DNM1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105518053-B aliphatic polycarbonate compositions and methods 诺沃梅尔公司 2017-07-21 — — CN claimed
WO-2024147345-A1 COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES ＡＰＢ株式会社 2024-07-11 — — WO disclosed
CN-118201905-A Cationic lipid 武田药品工业株式会社 2024-06-14 — — CN disclosed
US-20240182746-A1 POLYMER COMPOSITION COMPRISING POLYACRYLIC BLOCK COPOLYMER AND AROMATIC BASED POLYALKYLENEOXIDE AS DISPERSANT BASF SE (DE) 2024-06-06 — — US disclosed
WO-2024042211-A1 A POLYETHER-BASED DISPERSANT WITH A LIGHT STABILIZING EFFECT BASF SE (DE) 2024-02-29 — — WO disclosed
EP-4314155-A1 POLYMER COMPOSITION COMPRISING POLYACRYLIC BLOCK COPOLYMER AND AROMATIC BASED POLYALKYLENEOXIDE AS DISPERSANT BASF SE (DE) 2024-02-07 — — EP disclosed
CN-117447450-A Triazole compounds and their use as LPAR1 antagonists 武汉人福创新药物研发中心有限公司 2024-01-26 — — CN disclosed
WO-2024018761-A1 NEUTRAL LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 — — WO disclosed
WO-2024018762-A1 PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE 国立大学法人北海道大学 2024-01-25 — — WO disclosed
US-20240024252-A1 LIPID NANOPARTICLE NITTO DENKO CORPORATION (JP) 2024-01-25 — — US disclosed
EP-0003422-A1 Novel 4-(8X-6,11-dihydrodibenzo-(b,e)-thiepin-11-one-3-yl)-4-oxobutyric acids, methods of preparation, compositions and uses thereof SYNTEX (U.S.A.) INC. (US) 1979-08-08 — — EP disclosed
US-4130654-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, FRIBRINOLYTIC, MUSCLE RELAXANT SYNTEX (U.S.A.) INC. (US) 1978-12-19 — — US disclosed
US-4097579-A ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, MUSCLE RELAXANTS SYNTEX (U.S.A.) INC. (US) 1978-06-27 — — US disclosed
US-4089969-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, SMOOTH MUSCLE RELAXANT SYNTEX (U.S.A.) INC. (US) 1978-05-16 — — US disclosed
US-4087539-A ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, SMOOTH MUSCLE RELAXANTS SYNTEX (U.S.A.) INC. (US) 1978-05-02 — — US disclosed
US-4048330-A Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia SYNTEX CORPORATION (US) 1977-09-13 — — US disclosed
US-4009197-A 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof SYNTEX CORPORATION (PM) 1977-02-22 — — US disclosed
US-4000288-A ANALGESICS, ANTIINFLAMMATORY AGENTS, PYREXIA SYNTEX (U.S.A.) INC. (US) 1976-12-28 — — US disclosed
US-4000308-A ANTIINFLAMMATORY, ANALGESICS, ANTIPYREXIA SYNTEX (U.S.A.) INC. (US) 1976-12-28 — — US disclosed
US-3989839-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC SYNTEX (U.S.A.) INC. (US) 1976-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024252-A1 LIPID NANOPARTICLE LIPC, ACOX1, ABCB4 LMNA 1094/4885ACE2 2922/4885OPRM1 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.